Cantargia Ab

Pharmacia & Upjohn

Pharmcia & Upjohn

Agneta Svedberg

Karin Von Wachenfeldt

Kjell Sjöström

Thoas Fioretos

Marcus Järås

Cecilia Ann-Christin Malmborg Hager

Helena Ågerstam

Bo Nilsson

Per Gjorstrup

Kjell Sjostrom

Helena Agerstam

Marcus Jaras

Kjell SJÖSTRÖM

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody 'CAN04' to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.

Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

Methods of producing an IL-1 RAP antibodies

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.

Method of detection of IL1RAP on cells expressing the protein

Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer

The present disclosure provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1 RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody 'CAN04' to human IL1 RAP. The disclosure further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.

Use of quinoline-3-carboxamide compounds

Growing community of inventors

Lund, Sweden

Agneta Svedberg